Cargando…
Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors
The aim of this phase 1 study was to determine the effects of sapanisertib on the heart rate–corrected QT (QTc) interval in patients with advanced solid tumors. Adult patients with advanced solid tumors were enrolled to receive a single sapanisertib 40‐mg dose. Blood samples for pharmacokinetic anal...
Autores principales: | Patel, Chirag, Goel, Sanjay, Patel, Manish R., Rangachari, Lakshmi, Wilbur, Jayson D., Shou, Yaping, Venkatakrishnan, Karthik, Lockhart, A. Craig |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586797/ https://www.ncbi.nlm.nih.gov/pubmed/32488989 http://dx.doi.org/10.1002/cpdd.808 |
Ejemplares similares
-
Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017) -
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours
por: Moore, Kathleen N, et al.
Publicado: (2018) -
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
por: Voss, Martin H., et al.
Publicado: (2020) -
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
por: Alhalabi, Omar, et al.
Publicado: (2023) -
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)